Boehringer’s Hernexeos beats Bayer’s sevabertinib to the US.

Meanwhile, Royalty Pharma stakes $885m on $2.8bn sales by 2035.

Jazz’s Chimerix buy faces its big test.

The group has canned its first-generation project, hoping that a follow-on will reach more patients.

TAK-280 is among the group's discarded projects, although it’s a T-cell engager, not an ADC.

Data in HER2-mutated NSCLC still look good, and studies in HER2-amplified tumours continue.

Boehringer discontinues brigimadlin while others continue to struggle.

Tough equity markets as well as competitor developments prompt a narrowed focus.

The FDA will rule on a low dose of zongertinib in the summer.

While Cogent joins the FGFR party.